FY2025 EPS Estimates for Cencora Reduced by Leerink Partnrs

Key Points

• Leerink Partners has downgraded their FY2025 EPS estimate for Cencora to $15.95, from a previous forecast of $15.97, while the consensus estimate remains at $15.37.
• Cencora reported a quarterly EPS of $4.00, exceeding expectations by $0.21, with revenues of $80.66 billion.
• Insider selling has been noted, with CEO Robert P. Mauch and Chairman Steven H. Collis reducing their aggregate holdings by approximately 11.49% and 9.30%, respectively.

Cencora, Inc. (NYSE:COR - Free Report) - Equities researchers at Leerink Partnrs reduced their FY2025 EPS estimates for shares of Cencora in a research report issued on Monday, October 6th. Leerink Partnrs analyst M. Cherny now expects that the company will post earnings of $15.95 per share for the year, down from their previous forecast of $15.97. The consensus estimate for Cencora's current full-year earnings is $15.37 per share.

Cencora (NYSE:COR - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported $4.00 EPS for the quarter, beating the consensus estimate of $3.79 by $0.21. The business had revenue of $80.66 billion for the quarter, compared to analysts' expectations of $80.34 billion. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The firm's revenue was up 8.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.34 EPS.

Several other research firms have also recently commented on COR. Jefferies Financial Group boosted their price objective on shares of Cencora from $275.00 to $300.00 and gave the company a "hold" rating in a research report on Monday, June 30th. Weiss Ratings reaffirmed a "buy (b)" rating on shares of Cencora in a research report on Saturday, September 27th. Wells Fargo & Company boosted their price target on shares of Cencora from $337.00 to $354.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 13th. Finally, Morgan Stanley set a $330.00 price target on shares of Cencora and gave the stock an "equal weight" rating in a research report on Wednesday, July 16th. Nine investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $314.55.

Cencora Trading Up 1.1%

COR opened at $308.63 on Wednesday. The stock has a market capitalization of $59.84 billion, a P/E ratio of 31.75, a P/E/G ratio of 1.43 and a beta of 0.63. Cencora has a 12 month low of $219.69 and a 12 month high of $315.23. The firm's fifty day simple moving average is $295.45 and its 200 day simple moving average is $290.80. The company has a current ratio of 0.90, a quick ratio of 0.53 and a debt-to-equity ratio of 3.64.

Cencora Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Friday, August 15th were issued a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend was Friday, August 15th. Cencora's dividend payout ratio is currently 22.63%.

Insider Activity

In other Cencora news, CEO Robert P. Mauch sold 5,097 shares of the stock in a transaction dated Thursday, September 18th. The shares were sold at an average price of $290.00, for a total value of $1,478,130.00. Following the transaction, the chief executive officer directly owned 39,274 shares of the company's stock, valued at $11,389,460. This represents a 11.49% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Chairman Steven H. Collis sold 31,350 shares of the stock in a transaction dated Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the completion of the transaction, the chairman directly owned 305,913 shares in the company, valued at approximately $88,671,942.18. This represents a 9.30% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 55,993 shares of company stock worth $16,292,923. Insiders own 10.80% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Atlantic Edge Private Wealth Management LLC grew its position in shares of Cencora by 70.0% during the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company's stock worth $25,000 after purchasing an additional 35 shares in the last quarter. Cornerstone Planning Group LLC grew its position in shares of Cencora by 106.7% during the 1st quarter. Cornerstone Planning Group LLC now owns 93 shares of the company's stock worth $26,000 after purchasing an additional 48 shares in the last quarter. Hoey Investments Inc. acquired a new stake in shares of Cencora during the 1st quarter worth approximately $28,000. Costello Asset Management INC acquired a new stake in shares of Cencora during the 1st quarter worth approximately $28,000. Finally, Vermillion & White Wealth Management Group LLC boosted its position in shares of Cencora by 69.4% during the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company's stock worth $31,000 after acquiring an additional 43 shares in the last quarter. Institutional investors and hedge funds own 97.52% of the company's stock.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.